Accession Number:

AD1166361

Title:

Making the CASE: Chemopreventive use of Aspirin for Ovarian Cancer- Integrating Epidemiological Data to Evaluate Population Subgroups and Tumor Expression

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

GENEVA FOUNDATION TACOMA WA

Personal Author(s):

• Trabert, Britton

Report Date:

2021-10-01

Pagination or Media Count:

16

Abstract:

We hypothesize that the use of updated exposure information in cohort analyses will clarify and refine the ovarian cancer risk reductionassociated with aspirin, that there are subgroups of women who will derive the most benefit from daily aspirin use with respect to ovarian cancerchemoprevention, and that aspirin will preferentially reduce risk for ovarian cancers dependent on the tumor immune microenvironment.

Descriptors:

• biomedical research
• health
• public health
• data analysis
• ligation
• medical personnel
• women's health
• drug therapy
• ovarian cancer
• risk factors
• abstracts
• infrastructure
• neoplasms
• risk
• demographic cohorts
• department of defense
• organizational structure

Subject Categories:

• Medicine and Medical Research
• Pharmacology

Distribution Statement:

[A, Approved For Public Release]